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MicroRNA signatures in B-cell lymphomas
L Di Lisio1,2, M Sa´nchez-Beato2, G Go´mez-Lo´pez3, ME Rodrı´guez1,2, S Montes-Moreno1,2, M Mollejo4, J Mena´rguez5, MA Martı´nez6,
FJ Alves7, DG Pisano3, MA Piris1,2,8 and N Martı´nez1,2,8
Accurate lymphoma diagnosis, prognosis and therapy still require additional markers. We explore the potential relevance of
microRNA (miRNA) expression in a large series that included all major B-cell non-Hodgkin lymphoma (NHL) types. The data
generated were also used to identify miRNAs differentially expressed in Burkitt lymphoma (BL) and diffuse large B-cell
lymphoma (DLBCL) samples. A series of 147 NHL samples and 15 controls were hybridized on a human miRNA one-color
platform containing probes for 470 human miRNAs. Each lymphoma type was compared against the entire set of NHLs. BL was
also directly compared with DLBCL, and 43 preselected miRNAs were analyzed in a new series of routinely processed samples
of 28 BLs and 43 DLBCLs using quantitative reverse transcription-polymerase chain reaction. A signature of 128 miRNAs
enabled the characterization of lymphoma neoplasms, reﬂecting the lymphoma type, cell of origin and/or discrete oncogene
alterations. Comparative analysis of BL and DLBCL yielded 19 differentially expressed miRNAs, which were conﬁrmed in a
second conﬁrmation series of 71 parafﬁn-embedded samples. The set of differentially expressed miRNAs found here expands
the range of potential diagnostic markers for lymphoma diagnosis, especially when differential diagnosis of BL and DLBCL
is required.
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INTRODUCTION
B-cell non-Hodgkin lymphomas (NHLs) are a group of lympho-
proliferative B-cell disorders that include Burkitt lymphoma (BL),
chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma
(DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL),
marginal zone lymphoma/mucosa-associated lymphoid tissue
lymphoma (MZL/MALT), nodal marginal zone B-cell lymphoma
(NMZL), splenic marginal zone lymphoma (SMZL) and various less
frequent entities.1 These deﬁnitions are based on a combination of
clinical data and morphological, phenotypic and cytogenetic
features. The use of surrogate markers for gene and chromosomal
alterations speciﬁc to the different B-cell lymphoma types1 is also
useful at diagnosis.
Nevertheless, the distinctions between these disorders are
somewhat blurred and most exhibit signiﬁcant clinical and
molecular heterogeneity.1,2 New, consistent markers continue to
be required to improve the accuracy of lymphoma diagnosis and
therapy selection. An area of particular interest is the interface
between BL and DLBCL,3,4 two different lymphoma types that
require different treatment. Previous studies have demonstrated
the value of C-MYC translocations3 and gene expression proﬁling
data4 for this purpose, but new markers are needed to delineate
the boundaries between these two entities and to use this
knowledge to identify diagnostic markers.
In recent years, the study of a new type of non-coding small
RNA, microRNA (miRNA), has given renewed impetus to cell
differentiation and cancer pathogenesis studies.5 MiRNAs
post-transcriptionally regulate the expression of thousands of
genes, including key genes in cell differentiation and cancer
pathogenesis.6 Since evidence of the relationship between
miRNAs and cancer ﬁrst emerged, with the description of the
loss of miR-15/16 in CLL cases,7 an increasing number of speciﬁc
miRNA changes have been identiﬁed in many tumor types.5 The
diagnostic potential of miRNAs is linked to their role in cellular
differentiation, as demonstrated in hematopoietic cells and,
for instance, by miR-150, in B-cell differentiation.8 The potential
of using miRNAs for differential diagnosis of tumors and
hematopoietic malignancies has been recognized, for example,
in acute lymphoblastic and myeloid leukemias, where the
expression signatures of at least two of four miRNAs (miR-128a,
miR-128b, miR-223 and let-7b) distinguished the two tumor types
with about 95% accuracy.9 Altered miRNA expression has a role in
lymphoma development and potential diagnosis. MiRNA changes
are associated with CLL (loss of miR-15a/16)7 and SMZL (loss of
miR-29a and miR-29b-1),10 among others, and in both cases these
miRNAs were located in frequently lost chromosomal regions:
13q14 and 7q32, respectively. There are differential signatures
between the expression signature of patients with different
lymphoma types, such as DLBCL and FL.11 Furthermore, in DLBCL,
miRNAs are differentially expressed in the germinal center (GC)
and activated B-cell-like (ABC) subtypes; in particular, miR-21,
miR-155 and miR-221 were found to be upregulated in the ABC
subgroup.12,13
The purpose of this study is to test whether different B-cell
lymphoma types have speciﬁc miRNA signatures, and to apply this
knowledge to identify potential markers for distinguishing BL and
DLBCL. In addition, the markers described here could be
therapeutic targets in the treatment of B-cell lymphomas.
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MATERIALS AND METHODS
Sample selection
A series of 147 fresh-- frozen samples of NHL, including 12 BL, 29 DLBCL, 22
MCL, 17 SMZL, 18 CLL, 23 FL, 11 NMZL and 15 MZL/MALT, and 15 non-
tumoral samples (7 reactive lymph nodes, 4 tonsils and 4 spleens) were
collected. A formalin-ﬁxed, parafﬁn-embedded (FFPE) series of 28 sporadic
BL and 43 DLBCL samples were also investigated. Finally, an independent
series of FFPE samples corresponding to 66 lymphomas (8 BL, 8 CLL,
12 DLBCL, 9 FL, 8 MZL/MALT, 8 MCL, 8 NMZL and 5 SMZL) and 8 controls
(4 reactive lymph nodes, 3 tonsils and 1 spleen) was examined by
quantitative real-time-polymerase chain reaction (qRT-PCR) for miRNA
validation. CLL samples correspond to lymph node-involved CLL cases to
facilitate comparison with the other lymphoma types. All cases were
reviewed by a panel of three hematopathologists (SMRP, MAP, SMM)
according to the current World Health Organization criteria.1 All samples
were diagnostic, taken before the patient received therapy. The project
was approved by the ethics committee of the Instituto de Salud Carlos III
(ISCIII). The majority of the BL cases (11/12 frozen cases; 20/28 FFPE cases)
presented C-MYC translocation by FISH, whereas 31.7% (13/41) of DLBCL
FFPE cases were positive for C-MYC translocation. On the other hand, 60%
(15/25) and 40% (10/25) of DLBCL frozen samples were classiﬁed as
ABC and GC type, respectively, according to the classiﬁer of Wright et al.14
based on gene expression proﬁling data, with four cases considered as not
evaluable. FFPE samples of these cases permitted classiﬁcation in 44% non-
GC (11/25) and 56% GC (14/25)15 based on Hans immunohistochemical
classiﬁer.16 Finally, FFPE series of DLBCL used for qRT-PCR were classiﬁed as
54.76% non-GC (23/42) and 45.24% GC (19/42) (one case was not
evaluable).
MiRNA detection
RNA from fresh- frozen tissues was extracted with Trizol reagent
(Invitrogen, Carlsbad, CA, USA). Quality was assessed using a bioanalyzer
(Agilent Technologies Inc., Santa Clara, CA, USA), and 100 ng of total RNA
were hybridized on an Agilent 8 15K Human miRNA one-color platform
(Agilent Technologies Inc.) containing probes for 470 human miRNAs
according to the manufacturer’s guidelines.17 Data were extracted by
Feature Extraction software (Agilent Technologies).
For FFPE samples, RNA was extracted by phenol - chloroform standard
protocol after a deparafﬁnization step. RNA quality was assessed taking
into account 260/280 ratio and 260/230 ratio. QRT-PCR was performed
for 60 selected miRNAs according to the manufacturer’s protocol (Applied
Biosystems, Foster City, CA, USA).
Statistical methods
Between-array median normalization was carried out and signiﬁcantly
deregulated miRNAs were computed using the Signiﬁcant Analysis
of Microarray (SAM; http://www-stat.stanford.edu/~tibs/SAM/) method.
Each lymphoma type was compared against the whole set of samples.18
BL was also directly compared with DLBCL. MiRNAs with a false discovery
rate (FDR) o0.01 and a 41.5-fold (log2) change were considered to be
signiﬁcantly up- or downregulated between lymphoma types.
MiRNA target prediction was performed using the software analysis
tools included into the following websites: http://gencomp.bio.unipd.it/
magia/start (Magia), http://www.targetscan.org (targetscan) and http://
diana.cslab.ece.ntua.gr/pathways (Diana Lab).
The K-nearest neighbors method was also used for class recognition
(http://tnasas.bioinfo.cnio.es) to test whether these lymphomas were
classiﬁed correctly with the selected miRNAs.
Quantitative RT-PCR data were processed using the SDS 2.2 and Real-
Time StatMiner (Integromics, Granada, Spain) programs, and normalized
according to the most stable endogenous small RNA tested (RNU6B). DCt
values of BL and DLBCL were compared using a t-test (limma; available
at http://pomelo2.bioinfo.cnio.es). MiRNAs with an FDR o0.05 were
considered differentially expressed in the two groups. All clusters
were computed using the web resource GEPAS 4.0 (www.gepas.es). The
workﬂow is shown in Figure 1.
RESULTS
MiRNA signature of B-cell NHLs
MiRNA expression proﬁles of 147 NHL samples were studied.
A general view of the B-cell lymphoma miRNA signature is shown
in Supplementary Figure S1 comparing miRNA expression in
tumor samples with non-tumoral controls (tonsils and lymph
470 miRNAs; 8 types of B-cell NHL; 147 samples (Fresh Frozen)
(12BL, 18CLL, 29DLBCL, 23FL, 15MALT, 22MCL, 11NMZL, 17SMZL)
120 miRNAs classify
127 out of 147 cases
(86.4% accuracy)
128 significant
miRNAs
43 significant
miRNAs
95 miRNAs in common
Tnasas class prediction
model builder
Each lymphoma type
vs. the entire series
12BL vs. 29DLBCL
19 miRNAs confirmed
All samples
KNN. K=1 SAM(FDR<0.01, FC>1.5)
SAM
(FDR<0.01, FC>1.5)
Confirmation in a second series
of 28BL vs. 43DLBCL (FFPE)
SAM (FDR<0.05)
Figure 1. Workflow. The samples were analyzed first by SAM, comparing each lymphoma type against the whole series. In parallel, a class
predictor model was investigated for the 147 samples. Also, BL and DLBCL samples were compared by SAM, and then significant miRNAs
were analyzed in a second series of BL and DLBCL samples.
MiRNA signatures in B-cell lymphomas
L Di Lisio et al
2
Blood Cancer Journal & 2012 Macmillan Publishers Limited
nodes or spleens). The heatmap reveals a fairly homogeneous
expression pattern with a larger set of downregulated miRNAs in
tumor cells. The upregulated miRNAs have a more heterogeneous
pattern that varies with the lymphoma diagnosis.
The most strongly upregulated miRNAs compared with
non-tumoral controls were miR-212, miR-487b, miR-513 and
miR-770-5p, a set of miRNAs about which relatively little is known.
On the other hand, downregulated miRNAs were more frequently
observed. There was notable downregulation of let-7 family
miRNAs, which are downregulated in various types of cancer, and
key regulators of cell differentiation and apoptosis.19 Interestingly,
let-7a and let-7c loss participates in the genesis and maintenance
of the lymphoma phenotype in BL cells through C-MYC
regulation.20 On the other hand, miR-23b was reported to be
downregulated by C-MYC, playing a role in the MYC regulation of
glutamine metabolism, and energy and reactive oxygen species
homeostasis.21 The miR-200 family is another large family down-
regulated in this B-cell lymphoma series. MiR-200 has been
described, along with the let-7 family, as a key regulator of cell
differentiation, whose loss is associated with increased stemness
capacity.19 MiR-10 (a and b) was also downregulated. This family is
situated within the Hox cluster, and is also downregulated
in myeloproliferative disorders.22 MiR-15 and miR-16, already
described to be downregulated in CLL,7 were found to be
downregulated in the CLL cases in this study. MiR-155, which is
involved in the immune response and GC development, and is
upregulated in Hodgkin lymphoma,23 was found downregulated
here in the BL cases.
A selection of 14 deregulated miRNAs (9 downregulated and 5
upregulated) was analyzed by qRT-PCR to validate the microarray
data further. For this purpose, an independent series containing
66 lymphoma samples (8 CLL, 8BL, 12 DLBCL, 9 FL, 8 MZL/MALT,
8MCL, 8NMZL and 5 SMZL) and 8 controls (4 lymph nodes,
3 tonsils and 1 spleen) was used.
The miRNA expression observed by microarrays was conﬁrmed
by qRT-PCR (see Supplementary Figure S4). Nevertheless,
miR-487b, miR-212 and miR-770-5p presented a slight variability
among the different lymphoma types, especially SMZL and MZL/
MALT. This variability can be explained by the different localization
of SMZL lymphomas and NMZL, as SMZLs are localized in the
spleen and MZL/MALT lymphomas are localized in a variety of
different tissues (in this series: breast, eye, skin, salivary gland and
intestine).
To select a lymphoma miRNA signature, data from all tumor
samples, without previous normalization to controls, were studied.
SAM analysis enabled comparison of each lymphoma type with
the entire set of samples. A set of 128 miRNAs was considered
to be signiﬁcantly deregulated (FDR o0.01; 41.5-fold change in
log2) in one or more lymphoma types (Table 1). The heatmap of
the 128 signiﬁcant miRNAs is shown in Figure 2.
MiRNA capacity for class recognition was tested with the
K-nearest neighbors algorithm. Thus, 120 out of 470 miRNAs were
identiﬁed that classiﬁed the eight subclasses of lymphomas
(correct classiﬁcation rate: 86.4%) (Supplementary Table S1). In all,
95 of these miRNAs coincide with those identiﬁed as signiﬁcantly
differentially expressed by SAM analysis (in blue in Table 1).
The miRNA signatures found by SAM analysis for each
lymphoma type are described in more detail below.
Burkitt lymphoma. In all, 12 BL cases were analyzed. The majority
of them (11/12) showed C-MYC translocation. A total of 35
(14 upregulated, 21 downregulated) miRNAs were deregulated in
BL compared with the other NHLs. Interestingly, members of the
miR-17--92 cluster (miR-17-3p, miR-18a, mir-19a, miR-19b and miR-
92) were upregulated in BL. Among the downregulated miRNAs, we
found the let-7 family miRNAs that are commonly lost in different
neoplasias,20 miR-155, miR-146a and others already described as lost
in BL24 and the miR-29 family (a, b and c), which regulates p53.25
Chronic lymphocytic leukemia. In all, 14 miRNAs were upregulated
and 46 downregulated in CLL samples. MiR-197, which regulates the
tumor suppressor gene FUS1,26 was the most highly expressed miRNA
in these samples. MiR-595 and miR-483 were also upregulated, as has
been noted in Wilm’s tumor.27 Among the downregulated miRNAs,
we found miR-15a and miR-16, already described in CLL, where the
loss of the 13q14 minimally deleted region induces a clonal lympho-
proliferative disorder that recapitulates the spectrum of CLL-associated
phenotypes observed in humans.7 Other downregulated miRNAs were
miR-182, miR-199a*(5p), the let-7 family, miR-424, miR-10a, miR-7,
mir-126 and miR-218, whose loss of expression is related with the
activation of multiple survival pathways in various cancer models.28
Diffuse large B-cell lymphoma. No signiﬁcant differential miRNA
expression was found in this type of lymphoma by SAM analysis.
This could be due to the intrinsic heterogeneity of DLBCL cases as
an entity, which probably dilutes the miRNA expression differ-
ences with other types of lymphomas. This heterogeneity is
reﬂected by the Tnasas web resource class predictor analysis
results, where the DLBCL group has the highest error rate (27%;
Supplementary Table S1). Indeed, gene expression proﬁling data
in the series of DLBCL conﬁrm this heterogeneity, revealing that
60 and 40% of the cases are ABC type and GC type, respectively,
according to the classiﬁer of Wright et al.14 two DLBCL subtypes
with speciﬁc miRNA signatures categories.13,29
Follicular lymphoma. Two signiﬁcantly upregulated miRNAs,
miR-138 and miR-9 (5p and 3p), were found. Increased expression
of miR-9 was previously described in FL samples.11 MiR-9, which is
activated by MYC, has been shown to regulate nuclear factor-kB.30
Overexpression of miR-9 or let-7a reduces PRDM1/BLIMP1 levels,31
a ﬁnding of potential interest in FL cases, characterized by the
tightly regulated expression of BCL6 and PRDM1/BLIMP1.
Marginal zone lymphoma/MALT. Three out of eight miRNAs
signiﬁcantly upregulated in MALT lymphoma cases studied belong
to the miR-200 family (miR-200a, b and c). These miRNAs are
components of two clusters, miR-200a/200b/429 on chromosome
1p36.33 and miR-200c/141 on chromosome 12p13.31. The other
miRNAs located in these clusters, miR-429 and miR-141, were also
upregulated. The miR-200 family inhibits the initiating step of
metastasis, the epithelial --mesenchymal transition (EMT), by
maintaining the epithelial phenotype through directly targeting
the transcriptional repressors of E-cadherin, ZEB1 and ZEB2.32 The
only miRNA in MALT lymphoma cases downregulated relative to
the other types was miR-126* (corresponding to miR-126-5p), an
miRNA whose expression distinguishes acute myeloid leukemia
cases with common translocations.33
Mantle cell lymphoma. Only miR-126* was downregulated, as in
the case of MALT. Conversely, there were eight upregulated
miRNAs, for example, miR-182 and miR-183, which are upregu-
lated in colorectal cancer,34 and miR-200c, which was also
upregulated in MALT lymphoma cases. Downregulation of
miR-126* and upregulation of miR-181c, miR-182, miR-363,
miR-654 and miR-768-5p were also found in our previous study
after comparing MCL cases with non-tumoral controls (tonsils and
lymph nodes). In the same study, miR-182 was also upregulated in
MCL cell lines compared with mantle cell controls.17
Nodal marginal zone lymphoma. Two miRNAs, miR-370 and miR-
513, were downregulated in NMZL cases. MiR-370 has been shown
to be downregulated in gastrointestinal stromal tumors with 14q
loss35 and upregulated in acute myeloid leukemia patients with
t(15;17).36 In all, 61 miRNAs were upregulated relative to the whole
series. The most highly expressed miRNA in this series was
miR-150, followed by miR-26b. MiR-150 regulates the expression
of the transcription factor c-myb, and plays a key role in B-cell
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Table 1. Differentially expressed miRNAs in each type of lymphoma compared with the rest of samples
miRNA BL CLL DLBCL FL MALT MCL NMZL SMZL miRNA BL CLL DLBCL FL MALT MCL NMZL SMZL
1 hsa-let-7a -1.54 -2.24 - - - - 2.23 56- hsa-miR-218 - -2.63 - - - - 1.64 -
2 hsa-let-7c - - - - - - 1.86 66- hsa-miR-221 - - - - - - 1.63 -
3 hsa-let-7d -1.53 -2.16 - - - - 1.87 76- hsa-miR-223 - -1.62 - - - - 2.19 -
4 hsa-let-7e -1.70 -2.07 - - - - 1.84 -422-Rim-ash86- -1.77 - - - - 1.55 -
5 hsa-let-7f -1.67 -2.70 - - - - 2.48 96- hsa-miR-26a -1.54 - - - - - 2.08 -
6 hsa-let-7g -1.90 -2.01 - - - - 2.55 07- hsa-miR-26b -1.92 -2.11 - - - - 2.81 -
7 hsa-let-7i - - - - - - 1.63 17- hsa-miR-29a -1.64 - - - - - 1.89 -
8 hsa-miR-1 - - - - - - 1.96 27- hsa-miR-29b -1.74 - - - - - 1.63 -
9 hsa-miR-100 - -2.02 - - - - 2.07 37- hsa-miR-29c -2.72 - - - - - - -
10 hsa-miR-106a - -1.53 47------ hsa-miR-30b - - - - - - 1.66 -
11 hsa-miR-107 - -1.53 57------ hsa-miR-30e-3p - - - - - - 1.95 -
12 hsa-miR-10a -1.62 -2.58 - - - - 1.91 67- hsa-miR-30e-5p -1.82 - - - - - 1.69 -
13 hsa-miR-10b -1.67 -2.11 - - - - 2.60 ------13-Rim-ash77- 1.83 -
14 hsa-miR-125a - -1.68 - - - - 1.69 87- hsa-miR-328 - 1.51 - - - - - -
15 hsa-miR-125b - - - - - - 1.82 ------533-Rim-ash97- 1.56 -
16 hsa-miR-126 - -2.27 - - - - 2.33 08- hsa-miR-338 - -1.67 - - - 1.71 - -
17 hsa-miR-126* - -1.51 - - -1.58 -2.26 2.53 1.79 81 hsa-miR-340 - - - - - - 1.54 -
18 hsa-miR-127 - - - - - - - 1.56 82 hsa-miR-34a - -1.54 - - - - - -
19 hsa-miR-128b - - - - - - 1.52 ------b43-Rim-ash38- 1.50 -
20 hsa-miR-130b 1.61 48------- hsa-miR-363 -2.12 -2.59 - - - 3.26 - -
21 hsa-miR-133a - - - - - - 1.59 58- hsa-miR-365 - -1.79 - - - - 2.11 -
22 hsa-miR-133b - - - - - - 1.55 68- hsa-miR-370 - 1.89 - - - - -1.83 -
23 hsa-miR-136 - - - - - - - 2.00 87 hsa-miR-373* 1.73 - - - - - - -
24 hsa-miR-138 - - - 2.07 88---- hsa-miR-374 - -2.14 - - - - 2.18 -
25 hsa-miR-139 - - - - - - 1.62 2.94 89 hsa-miR-377 - -1.62 - - - - - -
26 hsa-miR-141 - - - - 1.54 - - -1.83 90 hsa-miR-409-3p - - - - - - - 2.11
27 hsa-miR-143 - -1.75 19------ hsa-miR-421 - - - - - - - 1.99
28 hsa-miR-144 - - - - - - - 3.22 92 hsa-miR-424 - -2.68 - - - - - -
29 hsa-miR-146a -1.79 -1.67 ----924-Rim-ash39------ 2.16 - - -
30 hsa-miR-146b - - - - - - 1.74 49- hsa-miR-432 - 1.97 - - - - - 1.89
31 hsa-miR-148a - -1.56 - - 1.51 59--- hsa-miR-451 -1.71 -2.18 - - - - 2.06 4.06
32 hsa-miR-148b - - - - - - 1.64 69- hsa-miR-453 - 1.55 - - - - - -
33 hsa-miR-150 -2.98 - - - - - 2.86 -p3-454-Rim-ash79- -1.54 - - - - 1.65 -
34 hsa-miR-152 - - - - - - 1.57 ------554-Rim-ash89- 1.76 -
35 hsa-miR-155 -2.12 - - - - - 1.59 99- hsa-miR-483 - 2.29 - - - - - -
36 hsa-miR-15b - -1.80 - - - - 1.84 001- hsa-miR-485-3p - 2.39 - - - - - -
37 hsa-miR-16 - -1.76 - - - - 1.88 101- hsa-miR-486 - - - - - - - 1.56
38 hsa-miR-17-3p 1.66 201------- hsa-miR-487a - - - - - - - 1.71
39 hsa-miR-17-5p - -1.55 301------ hsa-miR-487b - - - - - - - 1.99
40 hsa-miR-181c - - - - - 1.60 ------315-Rim-ash401-- -1.83 -
41 hsa-miR-182 - -2.90 - - - 1.71 501-- hsa-miR-520d - 2.00 - - - - - -
42 hsa-miR-183 - - - - - 1.61 601-- hsa-miR-520d* - - - - - - - 1.77
43 hsa-miR-18a 1.90 701------- hsa-miR-542-3p - - - - - - - 1.89
44 hsa-miR-18a* 1.66 755-Rim-ash801------- 1.66 - - - - - - -
45 hsa-miR-191 - - - - - - 1.70 901- hsa-miR-560 2.02 - - - - - - -
46 hsa-miR-192 - -1.55 - - - - 2.00 011- hsa-miR-574 1.76 2.83 - - - - - 1.53
47 hsa-miR-193b - -1.96 111------ hsa-miR-595 - 2.59 - - - - - 1.95
48 hsa-miR-195 -1.69 -2.00 - - - - 1.86 211- hsa-miR-609 - 1.51 - - - - - -
49 hsa-miR-197 1.81 2.93 311------ hsa-miR-625 - -2.82 - - - - 2.52 -
50 hsa-miR-199a* - -2.81 - - - - 2.19 411- hsa-miR-629 2.51 - - - - - - -
51 hsa-miR-199b - -2.55 - - 1.69 - 1.85 -2.12 115 hsa-miR-647 - 1.53 - - - - - -
52 hsa-miR-19a 2.05 -------056-Rim-ash611------- 2.05
53 hsa-miR-19b 1.69 711------- hsa-miR-654 - - - - - 1.67 - -
54 hsa-miR-200a - - - - 2.66 - 1.55 811- hsa-miR-663 3.32 - - - - - - -1.62
55 hsa-miR-200b - - - - 2.68 - 1.91 911- hsa-miR-7 - -2.40 - - - - - -
56 hsa-miR-200c - - - - 2.02 1.50 - -1.64 120 hsa-miR-766 - 1.58 - - - - - -
57 hsa-miR-203 - - - - 1.75 121--- hsa-miR-768-3p -1.71 - - - - - 1.95 -
58 hsa-miR-204 - - - - - - - 2.02 122 hsa-miR-768-5p -1.77 - - - - 2.00 - -
59 hsa-miR-206 - 1.81 321------ hsa-miR-9 - -2.00 - 1.67 - - - -
60 hsa-miR-20a - -2.12 421------ hsa-miR-9* - -2.69 - 1.87 - - - -
61 hsa-miR-20b - -2.08 521------ hsa-miR-92 1.52 - - - - - - -
62 hsa-miR-210 - - - - - - - -1.90 126 hsa-miR-95 - -2.05 - - - - 2.22 2.64
63 hsa-miR-212 - - - - - - - 1.53 127 hsa-miR-98 - -2.24 - - - - 2.09 -
64 hsa-miR-215 - - - - - - 1.85 821- hsa-miR-99a - - - - - - 2.56 -2.19
Abbreviations: BL, Burkitt lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FC, fold change; FDR, false discovery rate; FL,
follicular lymphoma; KNN, K-nearest neighbors; MALT, mucosa-associated lymphoid tissue lymphoma; MCL, mantle cell lymphoma; miRNA, microRNA; NMZL,
nodal marginal zone B-cell lymphoma; SMZL, splenic marginal zone lymphoma. MiRNAs differentially expressed in the different non-Hodgkin lymphoma
types. FC in log2 is listed for all miRNAs with FDR o0.01 and FC 41.5. Numbers in red and green refer to upregulated and downregulated miRNAs,
respectively. MiRNAs in blue are those also identified by KNN class prediction.
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differentiation.8 Interestingly, seven members of the let-7 family of
miRNAs, which are commonly lost in tumors, were signiﬁcantly
overexpressed relative to the other lymphoma types.
Splenic marginal zone lymphoma. In all, 26 miRNAs (20 upre-
gulated and 6 downregulated) were differentially expressed
in SMZLs. The cluster miR-144/451 is highly overexpressed in
SMZL. These two miRNAs are erythropoiesis regulators,37 a ﬁnding
that may be related to the splenic microenvironment. Among the
downregulated miRNAs, we found the miR-200c/141 cluster,
which was upregulated in other types of B-cell lymphomas in
this series (MALT and MCL).
Identiﬁcation of miRNAs differentially expressed in BL vs DLBCL
As a practical application of the data generated here, we
compared the DLBCL and BL miRNA signatures. Microarray data
from 12 frozen specimens of BL were compared with 29 DLBCL
cases using SAM (details of the series, such as C-MYC translocation,
ABC, GC, subgroups are described in Material and Methods
section). In all, 43 miRNAs had a 41.5-fold in log2 differential
expression and an FDR o0.01 (Figure 3). These miRNAs were
investigated further by qRT-PCR in an additional series of 28 BL
and 43 DLBCL FFPE samples.
Six of the miRNAs had low-efﬁciency qRT-PCR ampliﬁcation, and
were excluded from further analysis. Inefﬁcient ampliﬁcation could
be due to the low quality of the RNA (extracted from FFPE
samples), or to their generally low expression level.
Differential expression (FDR o0.05) was conﬁrmed in 19
miRNAs (Table 2 and Figure 4). Thirteen additional miRNAs had
the same tendency as observed in microarray analysis, but less
signiﬁcantly. Two miRNAs were signiﬁcantly expressed, but
oppositely with respect to the microarray. So, 32 of 37 miRNAs
followed the array tendency (Supplementary Table S2).
MiR-155 was the most signiﬁcantly lost miRNA in BL, conﬁrming
previous ﬁndings,23 followed by miR-29b and miR-146a, whereas
the most signiﬁcantly lost miRNAs in DLBCL were miR-17-3p,
miR-595 and miR-663.
MiR-29b, which is downregulated in BL cases, regulates TCL-1
expression,38 a protein that is aberrantly expressed in this type of
lymphoma and has been proposed as a diagnostic marker.18,39
This miRNA is also negatively correlated with MCL-1 expression,40
a key antiapoptotic protein of the BCL2 family, that is over-
expressed in high-grade lymphoid neoplasms.
MiR-146a was already known to play an important role in
inﬂammatory reaction and cancer.41 MiR-34b that was down-
regulated in BL is targeted by p53, and is involved in maintaining
self-renewal of pancreatic cancer stem cells, possibly by directly
modulating the downstream targets BCL2 and NOTCH.42
The 19 signiﬁcant miRNAs were submitted to the SOTA
algorithm for samples unsupervised clustering. Only 5 of 71 cases
were misplaced (7%): 4 DLBCL and 1 BL. As it is shown in
Supplementary Figure S2, DLBCL cases that cluster with BL do not
show any common feature in terms of GC/ABC type, C-MYC
translocation or BCL2 immunohistochemical expression, although
two of the cases carry on a C-MYC translocation. As some of the BL
cases in this study do not carry C-MYC translocation, we analyzed
C-MYC mRNA and protein expression levels. As shown in
Supplementary Figure S3 and Supplementary Table S3 in Supple-
mentary Information, C-MYC expression level does not signiﬁcantly
differ between BL cases with and without C-MYC translocation.
On the other hand, the cluster shown in Supplementary Figure S2
demonstrates that these cases do not cluster depending on C-MYC
translocation status or C-MYC expression level.
Figure 2. Differentially expressed miRNAs in B-cell lymphomas. In all, 128 miRNAs were differentially expressed in the series (FDR o0.01 and
fold change (FC)41.5) of 147 samples. For representation, data were normalized with non-tumoral controls (tonsils, reactive lymph nodes or
spleens).
MiRNA signatures in B-cell lymphomas
L Di Lisio et al
5
Blood Cancer Journal& 2012 Macmillan Publishers Limited
DISCUSSION
Lymphoma diagnosis is based on the integration of clinical and
histopathological data with chromosomal alterations and gene, or
protein, expression data. In recent years, there have been many
signiﬁcant advances in lymphoma classiﬁcation; nevertheless,
additional molecular markers enabling a better distinction of
speciﬁc lymphoma types and a more accurate prediction of
response to therapy are still needed. The addition of miRNAs to
the diagnostic algorithms is viable, given that qRT-PCR for miRNA
expression is feasible in parafﬁn-embedded tissues, and it has been
shown that the miRNA data generated in FFPE samples reproduce
the data generated in frozen specimens.13 In addition, the
identiﬁcation of miRNAs differentially expressed among lymphoma
types could improve our understanding of lymphoma pathogenesis,
ultimately enabling recognition of new therapeutic targets.
miRNA target prediction revealed interesting miRNA/gene
interactions that could give some light on how lymphomagenesis
takes place. For example, miR-133a and miR-23b, which are
lost in our series of lymphomas, target PAX5, a gene involved in
lymphocyte development and whose upregulation is related
to the development of different B-cell lymphoma types reviewed
by O’Brien et al.43
One of the most strongly lost miRNAs in our series, miR-31, is
predicted to regulate the expression of the B-cell receptor
pathway together with MAPK and JAK-STAT pathways.
Finally, target prediction tools showed some interesting genes
that are commonly lost in different B-cell lymphoma types, and
could be targeted by miRNAs upregulated in our series. Therefore,
miR-9 and miR-513 are predicted to target PRDM1, and miR-770-
5p and miR-212, whose predicted target gene is TNFAIP3.44,45
The expression of some of the miRNAs identiﬁed here
reﬂects their role in B-cell differentiation, as has been shown for
miR-17-5p, miR-20b, miR-223,46 miR-150(ref.8) and miR-9.46 In fact,
the transcription factors LMO2 (GC marker) and PRDM1/BLIMP1
(plasma cell marker), which have a key role orchestrating B-cell
differentiation, are found to be targets of some of these
miRNAs,46,47 which may suggest that the follicular lymphoma GC
phenotype may be dependent on the concerted action of multiple
miRNAs. Thus, miR-9, which is upregulated in FL cases, is involved
in PRDM1/BLIMP1 downregulation,46 which is consistent with the
downregulation of PRDM1/BLIMP1 observed in reactive and
Figure 3. MiRNAs differentially expressed between BL and DLBCL. In all, 43 miRNAs were significantly (FDRo0.01 and fold change (FC)41.5)
differentially expressed in a SAM analysis comparing microarray data of 12 BL vs 29 DLBCL.
Table 2. Confirmation of miRNA expression by qRT-PCR
MiRNA FDR Average FC Upregulated in
hsa-miR-155 o1.00E-07 2.67 DLBCL
hsa-miR-29b 3.00E-07 2.33 DLBCL
hsa-miR-146a 2.30E-06 1.97 DLBCL
hsa-miR-17-3p 2.30E-06 1.68 BL
hsa-miR-365 1.75E-05 1.59 DLBCL
hsa-miR-30b 2.92E-05 1.21 DLBCL
hsa-miR-595 3.74E-05 2.79 BL
hsa-miR-663 3.74E-05 1.17 BL
hsa-miR-573 0.0003 1.73 BL
hsa-miR-26b 0.0005 0.83 DLBCL
hsa-miR-374 0.0037 0.70 DLBCL
hsa-miR-520d 0.0037 1.57 BL
hsa-miR-92 0.0037 1.27 BL
hsa-let7f 0.0076 0.67 DLBCL
hsa-miR-516-3p 0.0096 0.83 BL
hsa-miR-9 0.0096 1.03 DLBCL
hsa-miR-629 0.0170 0.88 BL
hsa-miR-9* 0.0170 1.01 DLBCL
hsa-miR-34b 0.0502 0.80 DLBCL
Abbreviations: BL, Burkitt lymphoma; DLBCL, diffuse large B-cell
lymphoma; FC, fold change; FDR, false discovery rate; miRNA, microRNA;
qRT-PCR, quantitative real-time-polymerase chain reaction. List of 19
miRNAs differentially expressed between BL and DLBCL, confirmed by
qRT-PCR: FDR o0.05. FC is expressed in log2.
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neoplastic GC B cells,48 thus pointing to a possible cooperation of
BCL6 and miR-9 in regulating terminal B-cell differentiation.46 MiR-
223 has been shown to inhibit LMO2 expression,47 an observation
that correlates with the strong expression of miR-223 in NMZL
cases, a tumor that does not express LMO2 or other GC markers.
Interestingly, miR-155 expression is downregulated in CLL and
upregulated in NMZL cases, which probably reﬂects the observa-
tion that B cells lacking miR-155 generate reduced extrafollicular
and GC responses and fail to produce high-afﬁnity immunoglo-
bulin G1 antibodies,49 which is consistent with the data showing
that MZL cells have a striking capacity for colonizing GCs and
differentiating to become GC cells.
RAG1, BCL6 and PRDM1/BLIMP1 are genes regulated by multiple
miRNAs: at least eight miRNAs are predicted to target their
30-UTRs, thereby emphasizing the need for the tight regulation
of the expression of these transcription factors. MiR-127 is one
of the miRNAs already known to regulate BCL6 expression.50 Here,
it was found to be upregulated in SMZL cases, a tumor that lacks
BCL6 expression.1 Normal B-cell differentiation and neoplastic
B-cell phenotypes seem to be partially determined by the
reciprocal antagonism between BCL6 and PRDM1/BLIMP1 expres-
sion,51 which seems to be at least partially orchestrated through
the interaction of multiple miRNAs.
MiR-182, overexpressed in MCL cases, was recently found to
be overexpressed in MCL cell lines,17 where a role as regulator of
FOXO1, a putative tumor suppressor gene downregulated in
breast cancer, has been proposed.52
Some of the changes detected here reﬂect the already
established heterogeneity of several tumor types. Thus, DLBCL
had the most heterogeneous miRNA signature of all the
lymphoma types analyzed, extending previous observations.47 In
fact, heterogeneity of DLBCL has been characterized at the gene
expression level, where the distinction between GC GC) type,
ABC type and primary mediastinal large B-cell lymphoma
has demonstrable biological, prognostic and therapeutic implica-
tions.53 The series of DLBCL cases studied here reﬂects this
heterogeneity with a 60% of ABC-type cases and 40% of GC-type
cases in the series used for miRNA proﬁling. In fact, miRNA
signatures related with the molecularly deﬁned subgroups of
DLBCL based on the cell of origin have been found by different
groups.13,29
The heterogeneity is also reﬂected in C-MYC status; 32.5%
(13/40) of FFPE series used for qRT-PCR were positive for C-MYC
translocation. This uncommon high percentage of C-MYC translo-
cated DLBCL is due to the fact that this series of DLBCL is a
selection of DLBCL cases phenotypically similar to BL (44% non-GC
(11/25) and 56% GC (14/25), as the source of the cases was a
collection of DLBCL cases with features mimicking BL submitted
for reference diagnosis.
The causes of these miRNA expression gains and losses are still
to be investigated in many cases, although some can be attributed
to changes in DNA copy numbers in the chromosomal regions
where they are located. For instance, analysis of a deletion at
13q14.3 prompted the discovery of two physically linked miRNAs,
miR-15a and miR-16-1, which were targets of these deletions,7
and shown here to be lost in CLL. NMZL cases exhibited a gain of
miR-191 located at chromosome 3p21.31, an area of known gains
in NMZL.54
The data generated here could have a practical diagnostic
value. We have explored whether miRNA data could contribute to
the differential diagnosis of BL and DLBCL, a controversial issue
that requires new approaches.3,4,39 Despite the characteristic
association between C-MYC translocation and the diagnosis
of BL, a discrete number of DLBCL cases may carry the C-MYC
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Figure 4. Box plots of qRT-PCR results. A selection of significant miRNAs (BL vs DLBCL) confirmed by qRT-PCR is illustrated. Mir-146a, miR-155
and mir-29b were upregulated in the DLBCL group, whereas miR-17-3p, miR-92 and miR-663 were upregulated in the BL group. --DCt values
are represented in log2 scale; *denotes outliers.
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translocation.1 Furthermore, a group of cases with typical
histology of BL may lack the C-MYC translocation55 and some
association with the expression of selected miRNAs has been
described.56 Our results show that a few miRNAs could be of
diagnostic value. For example, BL cases show loss of miR-155 and
gain of multiple miRNAs belonging to clusters 17--92. Some of the
miRNAs that characterize BL cases are probably C-MYC targets, as
has been shown for the clusters 17--92 and other miRNAs.24,57
In this study, miRNAs upregulated by C-MYC were upregulated in
BL relative to other NHL cases (miR-17-3p, miR-18a, miR-19a, miR-
92 and miR-130b) and speciﬁcally when compared with DLBCL
(miR-17-3p). Other miRNAs downregulated by C-MYC were lost in
BL compared with other NHL cases (let-7 family, miR-146a and
miR-29 family), and some were conﬁrmed when BL was compared
with DLBCL (miR-29b and miR-146a). The expression of miR-155 in
BL has been controversial, but recent reports agree that BL lacks
miR-155 expression,24 as conﬁrmed here. In our study, it was the
most signiﬁcantly differentially expressed miRNA in BL compared
with DLBCL, with a substantial 2.67-fold (log2) change, meaning
that expression in DLBCL was around six times stronger than in BL.
This conﬁrms miR-155 downregulation in BL, making it one of the
most suitable markers for differential diagnosis. Nevertheless, a
model including all 19 signiﬁcant miRNAs or the most signiﬁcant
ones may increase the accuracy of the BL diagnosis as the
unsupervised cluster failed to classify only 7% of the samples, and
it can also form the basis of a better understanding of BL
pathogenesis. These data facilitate a next level of analysis, where
an independent series of BL, DLBCL and intermediate BL/DLBCL is
currently being studied to obtain a signature with a lower number
of miRNAs, which could potentially be used for diagnosis. Further-
more, a recently published paper by Lenze et al.58 deﬁnes a
signature of miRNAs that differentiates BL from DLBCL. Five of the
miRNAs described in that paper, expressed in DLBCL, are
conﬁrmed by the work presented here, supporting the potential
relevance of miRNAs in diagnosis.
Differences in miRNA signatures for different lymphoma types
may have multiple causes. As B cells at different stages of
maturation show speciﬁc miRNA signatures,59 the differential
expression of miRNAs between different lymphomas types may
reﬂect distinct miRNA proﬁles of the cell of origin, the normal
counterpart for each lymphoproliferative disorder. Alternatively,
these differences could be due to the presence of some acquired
recurrent genetic alteration of the speciﬁc lymphoma type, for
example, miRNAs contained in frequently lost chromosomal
regions, such as 13q14 deletion in CLL or 7q21 lost in SMZL.
In addition, some of the changes observed here could depend
on oncogenic changes in genes regulating the expression of
multiple miRNAs, as demonstrated for C-MYC and BCL6.
In the initial series of 147 samples, K-nearest neighbors analysis
correctly classiﬁed 86.4% of the samples. This rate might be even
higher if more cases were introduced. Even though miRNA
involvement in the pathogenesis of each speciﬁc lymphoma type
still needs to be explored, and validation in an independent series
of samples is recommended, the miRNA expression signatures
described here could be a useful additional tool enabling a more
accurate B-cell NHL diagnosis, in particular when BL vs DLBCL
differential diagnosis is required, and a better understanding of
B-cell lymphoma pathogenesis.
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